AI 对冲基金 · 大师信号(存档)

This is exactly the setup I pay for: the rate of change is going the right way on every line that matters. Revenue growth dipped to 20% in the Q4 TTM and has re-accelerated to 35-36%, while operating margin has gone 47 to 60 and net margin 43 to 56 without a single down quarter — margins inflecting up on re-accelerating revenue is the rarest combination in this business. TTM EPS is 136 versus 77 a year ago, and the sequential adds are getting bigger, not smaller (+10, +17, +26) — that's momentum building, not fading, with ROE climbing to 40% and debt/equity actually falling from 0.56 to 0.45, so there's no leverage landmine underneath it. At 31x trailing on numbers compounding near 80% with self-funded capex, the multiple says the market expects this to cool off; the filings say the opposite, and that disagreement is the asymmetry — size it up.

This is a fast grower, plain and simple: EPS went from 62.68 to 136.27 in two years, full-year earnings jumped 46% from 223.18 to 326.83, and the last two quarters ran up 59% and 78% year over year. You're paying 31 times earnings for growth in the 45%-plus range — a PEG around 0.7 or better, which is the kind of math I like to find, not the kind you pay up for a story. The story checks out down the line: 36% revenue growth flowing through to wider margins (gross 0.58 to 0.68, net 0.43 to 0.56), ROE climbing from 0.29 to 0.40, and book value compounding 24% a year. The balance sheet is a fortress — debt/equity down from 0.56 to 0.45, current ratio near 2.5, free cash flow per share piling up — so this one survives a bad year, and chips always get a bad year eventually; that's the only reason I'm not at 95.

I inverted this and could not find the rot: gross margin went from 58% to 68%, operating margin from 47% to 60%, return on equity from 29% to 40%, and debt-to-equity fell from 0.56 to 0.45 while revenue grew 36% — that is a business getting better on every axis at once, not an accounting mirage. Book value compounding at 24% a year with a 2.46 current ratio and no leverage problem is the signature of a genuine franchise, and the one honest blemish is capital intensity — free cash flow runs about 60% of net income because the thing eats capex to stay ahead, which is the toll this business pays and always will. At 31 times earnings you are paying roughly three and a half times book for a 40% return on that book, and that arithmetic does not require me to believe anything stupid. I'd remind you semiconductors are cyclical and a 36% growth year is not a permanent condition, so you buy this expecting to sit through an ugly trough, not to flip it.

This is a business I can understand in its economics if not its physics: it takes in orders, earns a 68% gross margin and a 60% operating margin, and those margins have widened ten points over the stretch shown while revenue grew 36% — that is pricing power you cannot fake, and it shows up as return on equity climbing from 29% to 40%. Management has compounded book value at 24% a year while paying down leverage from 0.56 to 0.45 debt-to-equity and keeping the current ratio near 2.5, which is the kind of quiet, sensible capital allocation I look for rather than the kind that announces itself. At 31 times earnings the market is not handing me a gift, but a business earning 40% on equity and growing a third a year is worth more than a fair company at a cheap price, and the price does not demand perfection. My reservation, and it is why I stop short of full conviction: free cash flow runs well below reported earnings because the furnaces must be constantly rebuilt, and today's gross margin is the best in the record shown — I would want to own this for ten years knowing a cyclical trough would test both.

The enterprise itself is beyond reproach by my standards: a current ratio of 2.46, debt to equity reduced from 0.56 to 0.45, uninterrupted and rising earnings across every period shown, and book value per share compounding near 24% — this is a strong and well-financed concern, not a speculation. But the price is another matter entirely. At 31.3 times earnings and, by my arithmetic (136.27 EPS × 31.27 = roughly 4,260 a share against 1,248 of book), some 3.4 times book value, the multiplier product stands near 107 where I insist upon 22.5 — the buyer is paying nearly five times what I would call a prudent price for demonstrated results, and thereby purchasing the next decade's projected earnings in advance. A sound business bought at a price that capitalizes hope is still a poor investment; I would hold this on the watch list and let Mr. Market's enthusiasm exhaust itself before committing a dollar.

Revenue growth troughed at 56% in FY26/Q2 and has re-accelerated every quarter since — 56, 62, 73, 85, 106. That is second-derivative positive four quarters running in a company already doing $190B of net income, which almost never happens at this scale. Gross margin rebuilt from 61% to 75% and operating margin from 49% to 66% and is holding at the highs, while trailing EPS went 0.78 to 2.48 a quarter and book value per share nearly tripled off internally generated cash — D/E at 0.40 and a 4.6x current ratio mean there's no leverage time bomb here. And the market is paying 26.8x for it, a multiple that says consensus believes this growth mean-reverts hard and soon; the trend says otherwise, and that gap is the whole trade. I'd size this up — the only things I'd watch are the net margin tick from 71% to 62% and FCF/share falling to 0.89 from 2.02, which smells like working-capital build, not demand rolling over; if that turns into a receivables problem instead, I'm out, but you don't get accelerating revenue, peak margins and a sub-30 multiple in the same name without swinging.

This is a fast grower of the rarest kind — quarterly EPS has marched from $0.80 to $2.48 in eight quarters, revenue growth actually re-accelerated from 56% to 106%, and operating margin is at its best in the series at 66%. You're paying 26.8 times earnings for a business compounding well north of 60%, so the PEG is somewhere around 0.25 — that's the kind of math that made money in Magellan, and the balance sheet backs it up with a 4.6 current ratio and only 0.40 debt-to-equity. Two things keep me from banging the table: free cash flow per share fell to $0.89 against $2.48 of reported EPS, which means the earnings aren't turning into cash the way they did a year ago, and sequential EPS barely budged from $2.42 to $2.48. At five trillion dollars it can't double forever, but until the earnings stop growing I'd own it — earnings drive stock prices, and these earnings are still going the right way at a multiple that hasn't priced it in.

Ten consecutive periods of return on equity above 100% — not one lucky year, every year — with 75% gross margins, 66% operating margins, and revenue still doubling off a base this large. Book value per share has compounded at 74% while debt to equity sits at 0.40 and current assets cover current liabilities four and a half times over; this business is drowning in its own cash, not consuming capital, with FY2026 free cash flow of $4.01 per share against $4.98 of earnings. At 26.8 times trailing earnings you are not being asked to believe anything stupid — you are being asked to believe the company merely stays extraordinary rather than becoming more so, which is a rare bargain in a mania. The one thing I don't like: cash conversion in the latest quarter fell to $0.89 of free cash flow against $2.48 of earnings while leverage crept from 0.31 back to 0.40 — receivables and inventory are building, and if that persists it is the first crack in a business whose entire earnings power depends on a handful of buyers continuing to double their own capital spending.

The economics here are about as good as I've ever seen on paper — 75% gross margins, 66% operating margins, a 117% return on equity, book value per share compounding at 74%, almost no debt at 0.40 and a current ratio near 4.6. But I don't know how to handicap a chip designer ten years out; returns that extraordinary are a magnet for every engineer and every deep-pocketed customer on earth, and nothing in these numbers tells me the moat holds when the buyers become the builders. Two things nag at me: cash conversion has slipped — $4.90 of half-year earnings produced only $2.91 of free cash per share, against 80% conversion the prior year — and leverage has crept up from 0.31 to 0.40 while receivables and inventory swallow the profits. At 26.8 times trailing earnings the price isn't foolish for this quality, but a $5.1 trillion valuation requires the boom to keep booming, and when I can't tell a peak from a plateau I sit still rather than guess.

The balance sheet is beyond reproach — a current ratio of 4.59 and debt to equity of 0.40 would satisfy the most timid defensive investor, and earnings have been positive throughout the brief record shown. But I am asked to pay 26.8 times earnings and, with book value of $9.50 against an implied price near $66, some seven times book; the product of those two multipliers is roughly 188 where I insist upon 22.5, and no balance sheet however sturdy can supply a margin of safety at eight times my limit. A return on equity above 100 percent is not a permanent endowment but an invitation to competition, and the record here spans barely two years of extraordinary revenue expansion — 106 percent in the latest twelve months — which is precisely the sort of trajectory the market extrapolates and the future declines to honor. I do not doubt the enterprise; I decline the price, for what is being purchased is not demonstrated earning power but a decade of hoped-for continuation of it.

This is the rarest thing in markets: a business where the second derivative is positive on every line at once. Revenue growth went 29% → 39% → 48% → 63% → 70% → 85% → 93% — that's acceleration, not a base effect, and operating margin went from 11% to 47% while it happened. EPS is compounding off the same curve (0.09 → 0.14 → 0.20 → 0.25 → 0.36 → 0.44), ROE tripled to 38%, FCF/share is building, and the balance sheet is getting cleaner, not levered — D/E down to 0.18 with a 7x current ratio, so there's no blow-up mechanism here. Yes, 147x says the market already believes in greatness, but a multiple that high is priced off an extrapolated trend, and the trend is still getting faster rather than fading — I'll own this while the rate of change is with me and I'll be gone the first quarter growth or margin stops making a new high, because at this price the downside on a rollover is violent.

This is a genuinely wonderful business by the numbers: 85% gross margins, operating margins that climbed from 1% to 47% in eight quarters, returns on equity up from 11% to 38%, book value compounding at 41% a year, and a fortress balance sheet with 0.18 debt-to-equity and a 7.2 current ratio. But I'm being asked to pay 147 times earnings and roughly 130 times free cash flow — about $412 billion for a company generating some $3 billion of cash — which means everything has to go right for a decade before I earn my first honest dollar. I'd also note that net margin of 55% sits above the 47% operating margin, so a good slug of those earnings is coming from interest and tax items rather than the business itself, and I confess that predicting what government and enterprise software contracts look like in 2036 sits outside the circle I know well. Wonderful company, but this price demands perfection; I'd rather admire it from the sidelines and wait for the market to offer it to me at a price that leaves room for me to be wrong.

This is a textbook fast grower and then some — revenue growth has accelerated from 29% to 93%, operating margin went from 11% to 47%, and quarterly EPS marched from $0.03 to $0.44 without a stumble, all on a balance sheet with almost no debt (D/E 0.18) and a 7x current ratio. The trouble is the price: at 146x earnings you're paying up for a story that everyone on the planet already knows, and a PEG that only looks reasonable if you capitalize triple-digit growth that no company sustains for long. I like knowing what I own here — the earnings are real and the cash flow is real — but at this multiple the stock needs years of perfection just to stand still, and one quarter of deceleration takes half the price with it. Fine company, fully priced; I'd want to own it a lot cheaper than $412 billion.

The business itself is the real thing — 85% gross margins, operating margin up from 1% to 47% in eight quarters, ROE compounding from 11% to 38%, book value per share growing 41% a year, almost no debt, a current ratio of 7, and free cash flow that actually exceeds reported earnings. I have no quarrel with the enterprise; I have a violent quarrel with the price. At 147 times earnings on roughly $5 billion of revenue, you are paying about eighty times sales for a company whose net margin of 55% sits above its 47% operating margin — meaning a healthy slice of that bottom line is interest income and tax bookkeeping, not the business earning it. To make money here you must believe earnings grow tenfold and the crowd still pays a rich multiple at the end of it; that is not investing, that is standing on a chair and hoping the ceiling rises. I would rather admire it from across the street.

The enterprise itself is unobjectionable: a current ratio of 7.23, debt to equity of 0.18, and earnings that have been positive and rising in every period shown — this is a fortress balance sheet, and I grant it fully. But at 146.67 times earnings and roughly 15.7 times book value ($64.53 a share against $4.11 of book), the product of the two multiples exceeds twenty-two hundred where I would ask for twenty-two; the buyer at this price is paying some $412 billion for $0.44 of annual per-share earnings and fifty cents of free cash flow. That price does not discount the future — it discounts the hereafter, and no margin of safety whatever remains if growth of 93% decelerates even modestly. The record is also brief, barely two years of it, which is thin evidence on which to capitalize such expectations; a sound company bought at an unsound price is a speculation, and overvaluation of this magnitude is itself the bearish fact.

The rate-of-change here just turned the right way: TTM revenue growth had been decaying toward 36% through mid-2025 and has re-accelerated to 62-63% in the last two prints, while gross margin went 27% to 36% and operating margin compressed its loss from -48% to -25%. Just as important, they took the balance sheet off the table — D/E from 2.10 to 0.20, current ratio to 5.5x — so the one thing that blows you up in a cash-burning story, leverage into deterioration, is gone. What holds me back from swinging big is the price: at roughly -234x earnings, which backs into something near 50x trailing sales with FCF per share still negative and getting worse, the market already believes most of this story, and the book value per share going 0.64 to 5.84 tells me a good chunk of the growth was bought with issued stock. Real inflection, expensive entry — I own it, I don't max out on it, and if revenue growth rolls back toward the 30s I'm gone the same day.

Rocket Lab is a fast grower on the top line — revenue up 62% and gross margin climbing from 27% to 36% — but it has never earned a nickel, so there's no PEG to compute and nothing to anchor the price to. You're being asked to pay $37.8 billion for a business with a -21% net margin, negative free cash flow every single period, and a P/E that's a negative number; the book value per share is marching up because they keep selling stock, not because they're earning money. The balance sheet is the one thing I like — debt/equity down to 0.20 and a 5.5x current ratio buys them time — and the losses are genuinely narrowing, so this isn't a company about to fall over. But earnings drive stock prices in the long run, and at this price the story is already in the stock while the earnings are still a promise; I'll wait until I can see profits and count them.

Rockets are a wonderful thing to watch and a hard thing to own — this business has never earned a dime on my money, with return on equity averaging negative 29% and free cash flow negative in every period shown. The improvements are real: gross margin has climbed from 27% to 36%, revenue grew 62%, debt-to-equity fell from 2.10 to 0.20, and the current ratio is a comfortable 5.48 — but that book value per share compounding from $0.64 to $5.84 came from selling stock to enthusiastic investors, not from retained earnings, and that is the shareholder paying for his own growth. At $37.8 billion for a company with no profits and a P/E that is meaningless because the E is negative, the market is pricing a decade of flawless execution into a capital-hungry business I cannot appraise with any confidence. I would rather watch this one from the porch; if it becomes the enterprise its owners hope, there will still be money to be made after it proves it can earn a return on capital.

Ten trailing periods and not one dollar of profit — ROE averaging negative 29 percent, net margin negative 35, and free cash flow per share negative in every single period without exception. The book value CAGR of 156 percent is not compounding, it is dilution: equity per share climbed from $0.64 to $5.84 while EPS stayed negative the entire way, which means the shareholders funded the growth and got nothing back, and the debt-to-equity drop from 2.10 to 0.20 was bought the same way. Yes, gross margin improved from 27 to 36 percent and revenue grows 60 percent, and that is a real business getting better — but $37.8 billion of market value for an enterprise that consumes capital every quarter requires believing in a profitability no line in this table has ever demonstrated. I would rather miss this one than own it at a price that only works if you squint past a decade of losses.

In ten consecutive trailing periods this enterprise has not earned a single dollar for its owners — net margin averaging -35%, return on equity -29%, and free cash flow negative in every column — so the P/E of -234 is not a multiple at all but an admission that there is nothing to capitalize. The balance sheet alone is respectable: a current ratio of 5.48 and debt to equity fallen from 2.10 to 0.20 would satisfy my test of financial strength, but I note that book value per share rose from $0.64 to $5.84 while the company lost money throughout, which means that equity was purchased from shareholders, not earned for them. Against $5.84 of book the market asks roughly $18.70 a share, some 3.2 times book, and nearly $38 billion for a business whose demonstrated earning power is a deficit — the entire price rests on revenue growth of 62% and a gross margin creeping toward 36%, which is to say on the future, which no man can underwrite. A defensive investor buys demonstrated earnings at a discount; here he would be buying hope at a premium, and I decline.

This is a fast grower hiding inside the biggest company in the market — revenue growth actually accelerated from 15% to 18%, and EPS went from $13.71 to $18.01, better than 30% (call it mid-20s if you back out the odd Q2 where net margin jumped to 47%, which smells like a one-time item). At a 28 P/E against that growth, the PEG is around 0.9 to 1.1, which means you're paying roughly a dollar for a dollar of growth — not a giveaway, but not paying for a story either. The balance sheet got better, not worse: debt/equity down from 0.80 to 0.71, ROE steady at 34%, book value per share compounding 21%, and operating margin at 47% with gross margin off only a point. The one thing that nags me is free cash flow per share slipping from $9.64 to $9.02 while EPS climbed — they're plowing half of reported earnings back into the ground, so if that spending stops producing 18% revenue growth, the multiple won't hold.

Thirty-four percent returns on equity in every single period shown, forty percent net margins, book value per share compounding at twenty-one percent, and leverage falling from 0.82 to 0.71 while revenue growth accelerates from twelve to eighteen percent — this is the kind of business you cannot construct on purpose, and it is not earning those returns by heroic assumptions or borrowed money. At 28 times earnings against thirty-one percent EPS growth, the price is fair; it is not the mania price a business like this usually commands. The one thing that would make me look like a fool: free cash flow per share went backwards, 9.64 to 9.02, while earnings leapt thirty-one percent, which means the entire increment and then some went into the ground as capital spending — on that measure you are paying north of fifty times, and an asset-light toll booth is quietly becoming a capital-intensive one. I own the quality and the fair multiple and I accept that the capex bill is the whole argument against me.

This is a marvelous business and it sits squarely in the part of my circle I've come to understand: 34% returns on equity year after year, 68-cent gross margins, 47-cent operating margins, and revenue still compounding at 18% off an enormous base — that is a toll bridge, not a commodity. Management has compounded book value at 21% a year and trimmed debt-to-equity from 0.80 to 0.71 while earnings per share jumped from $13.71 to $18.01, so I've no quarrel with the stewardship. My hesitation is that the cash register has stopped keeping pace with the income statement — free cash flow per share actually slipped from $9.64 to $9.02 while earnings rose 31%, meaning barely half of reported profit is showing up as owner earnings, and the current ratio has eased from 1.40 to 1.23; at 28 times earnings and better than 50 times free cash flow, you are paying roughly a 1.8% cash yield and betting the capital being poured in earns its keep. I'd own this company happily for ten years and would back up the truck on a bad day in the market, but at today's price I'm content to sit on my hands rather than pay for perfection.

The top-line inflection already happened and it's now a plateau, not an acceleration — revenue went from 12-13% in the middle of FY25 to 17-18%, and it has sat at 18% for four straight quarters. What's actually inflecting right now is the wrong line: operating margin has walked down every single quarter of FY26 (49, 47, 46, 45) and gross margin is off 200bps, while FCF per share went backwards to 9.02 from 9.64 even as EPS printed +31% — that gap is the AI capex bill showing up in cash before it shows up in the P&L, and Q2's 47% net margin looks like a one-timer flattering the annual number. At 28x on 18% growth with a 40% net margin and D/E down to 0.71 from 0.80, the price isn't the problem and there's no leverage accident here, so I'm not short. But I don't swing at a business whose revenue curve has stopped steepening while its margin and cash conversion curves have started bending down — the asymmetry isn't there, and the correct size is zero until either the margin rolls back up or the multiple comes to me.

This is unquestionably a fine enterprise — a 34% return on equity, 40% net margins, and earnings that have risen from $13.71 to $18.01 per share without a single loss in the record shown — but the defensive investor buys businesses, not reputations, and the price here is the whole of the matter. At 28.16 times earnings and roughly 8.5 times a book value of $59.58 per share (a price near $507 against $3,753.6B of market capitalization), the product of the two multiples exceeds my limit of 22.5 by more than tenfold, leaving an earnings yield of 3.5% and no margin of safety whatsoever. The balance sheet, moreover, is merely adequate rather than strong: a current ratio of 1.23 sits below my minimum, and debt at 0.71 times equity is real leverage, though I note it has improved from 0.80. I am asked to pay for two decades of assumed prosperity in advance; the quality is demonstrated, the price is speculation, and overvaluation of this magnitude is itself the unfavorable fact — I would add that two years of filings is a thin record on which to judge stability at all.

The tape here is a reacceleration, not a mature compounder rolling over: revenue growth has gone 9% → 13% → 13% → 14% → 17% → 20% across the last six prints, gross margin has walked 48% to 52%, and operating margin is inflecting from 10-11% up to 14% — top line and unit economics improving at the same time, which is the rarest and most valuable combination there is. Meanwhile the market is paying 20x for it, a multiple that says 'big slow retailer'; the trend says something is compounding faster every quarter, and that gap is the whole trade. Two things keep me from backing up the truck: the 31% net margin and $5.81 EPS are plainly flattered by something below the operating line — op margin is only 14%, so the 'real' multiple is far higher than 20x — and free cash flow per share has gone negative (-1.68, -0.82) on a capex binge against D/E near 1.0. I'll own it because the revenue and operating-margin inflection are real and the price hasn't recognized them, but the negative FCF is the line I watch; if growth decelerates while the spend continues, this flips fast.

This is a fast grower that's speeding up, which almost never happens at this size — revenue growth went from 9% to 20% over six quarters, gross margin climbed from 47% to 52%, operating margin from 11% to 14%, and ROE from 23% to 31%. Full-year earnings went 5.49 to 7.20, up 31%, so at a P/E of 20 you're paying well under the growth rate; even if I strip out the odd windfall in the last two quarters — net margin of 31% against a 14% operating margin is a paper gain, not the business — I get roughly 30 times for roughly 30% growth, a PEG near one. Two things keep me from pounding the table: free cash flow per share has gone from $3.05 to negative, because every dollar of earnings is going back into capital spending, and debt-to-equity sits right at 1.0 with a current ratio barely above one. I own it for the operating earnings, which are visible and compounding — but I'd watch the cash, because a growth story that never converts to cash eventually stops being a growth story.

This is a fine business and getting finer — gross margin has climbed from 47 to 52 cents on the dollar, returns on equity sit in the mid-twenties, and book value per share has compounded near 40% a year from $24 to $51. But I don't trust the headline: a 20x multiple rests on a trailing net margin of 31%, roughly triple the 13% this company normally earns, and one good quarter's windfall is not owner earnings; normalize it and you're paying forty-odd times for a business whose free cash flow per share has gone from $3.05 two years ago to negative today. The retail side I understand; the cloud and the enormous capital being shoveled into it I understand less, and a current ratio of 1.03 with debt about equal to equity leaves no cushion if that spending doesn't earn its keep. Wonderful company, but at $2.7 trillion with cash going out the door faster than it comes in, I'd rather sit with my thumb in my mouth than pay up for perfection.

The headline P/E of 20 is a mirage: net margin jumped to 31% while the operating margin barely moved to 14%, which means better than half the reported $5.81 of earnings came from something other than selling goods and computing — mark-ups, not operations. Strip that out and you are paying something closer to fifty times what the business actually earns, for a company whose free cash flow per share went from $3.05 in fiscal 2024 to $0.71 in fiscal 2025 and is now negative in both recent quarters. The underlying franchise is genuinely excellent — 22-31% returns on equity every period shown, gross margin climbing from 47% to 52%, revenue reaccelerating to 20%, book value compounding at 40% — and I will not call a business like that bearish. But book value compounding while cash goes out the door is capitalized capex dressed up as progress, and I have no way from these numbers to know whether those data centers will earn their cost of capital. Great business, accounting I don't trust, price I won't pay — it sits in the too-hard pile.

The defensive investor's first question is not what Amazon may become but what it now owns and owes, and here the answer is unsatisfactory: a current ratio of 1.03 against my requirement of 1.5, debt equal to equity at 0.99, and free cash flow per share that has turned negative (-0.82 and -1.68 in the two most recent periods) while reported earnings climbed. A weak balance sheet disqualifies regardless of prospects. Nor does the price supply the cushion that might excuse it — at 20.44 times earnings and roughly 2.3 times the $51.14 book value, the product of the two multiples is near 47 against the 22.5 I permit, and the earnings themselves invite suspicion, since a net margin of 0.31 against an operating margin of 0.14 means the greater part of that profit did not come from selling goods. Strip out that windfall and the multiple is considerably dearer than it appears; the record shown covers barely two years, which is no substitute for the decade of demonstrated stability I insist upon.

The inflection is real and I won't pretend otherwise — revenue went from -52%, -42%, -18% through 2025 to +199% and +185% in the last two prints, gross margin ripped from 29% to 43%, and the operating loss ratio halved from -11.9x to -5.5x. But look at what you're paying for it: roughly $27M of trailing revenue against a $5.2B cap, call it 190x sales, and they still lose ten dollars for every dollar they book. The market isn't missing this inflection, it's already paid for the next five of them — and that 2026 growth is partly a rebound off a base that collapsed 34% the year before, so the two-year stack is far less impressive than the headline. I won't short it either: D/E is 0.21, current ratio still near 4, no leverage to blow them up and an improving top line is the worst thing to be short — but with the trend and the price in violent agreement, there's no asymmetry here, and the correct size is zero until either the multiple comes in or the acceleration proves it isn't a base effect.

There's no category here I can put this in — a company with an operating margin of minus 546% isn't a fast grower, a stalwart, or a turnaround, it's a research project with a ticker. You can't run the PEG test when the P/E is negative eighteen and the TTM EPS is minus sixteen cents, and the one quarter that showed a positive net margin came from something below the operating line, not from selling anything. The balance sheet is genuinely clean — debt/equity 0.21, current ratio near 4, book value per share climbing — but that book value grew by issuing stock into the enthusiasm, not by earning money, and it's still only $1.61 a share against a $5.2 billion market cap. Revenue tripling off a base this small is a headline, not an earnings stream, and in the long run earnings are the whole game; I'd let someone else pay for the story.

Quantum computing sits well outside my circle of competence, but I don't need to understand the physics to read the arithmetic: operating margins of negative 546%, ROE averaging negative 90%, and free cash flow per share that has been red in every single period shown. The book value per share 'compounding' at 93% isn't earnings piling up — it's stock sold to strangers to fund the losses, which is the opposite of the owner-friendly capital allocation I look for. And the market asks $5.2 billion for a business with a negative P/E, gross margins drifting down, and revenue so small that a 185% jump barely dents a 10% operating loss ratio. I'd rather own a fair company at a wonderful price than pay a wonderful price for a promise; this is a lottery ticket dressed up as a balance sheet, and I'll pass and stay passed for the next ten years.

The first test of a defensive investment is that there be earnings to value, and here there are none: operating margins of roughly negative 546 percent on the latest twelve months mean the enterprise spends some six dollars to collect one, and the record shows losses in eight of the ten periods, with the two positive EPS figures owing to items other than operations. The balance sheet is the one creditable feature — a current ratio near 3.9 and debt to equity of 0.21 — but that cash was raised by selling shares, not earned; book value per share nearly doubled while shareholders' equity was consumed at a 90 percent average negative return. Against $1.61 of book value the market asks about $2.98 a share, a $5.2 billion capitalization for a company with no demonstrated earning power and negative free cash flow in every period shown; there is no P/E to compare with fifteen because there are no E. This is not a bargain awaiting recognition but a subscription to a hypothesis, and a price that capitalizes hope is a bearish fact, whatever the science may eventually prove.

Here is a business that loses roughly five to twelve dollars of operating profit for every dollar of revenue it books, has never earned a positive return on equity in any period shown, and has burned free cash flow every single quarter — and the market is paying $5.2 billion for it, something like ten times a book value that exists only because they keep selling stock to strangers. The two 'profitable' quarters are a joke: net margin turns positive while operating margin sits at -590%, which means the earnings came from marking paper up and down, not from selling anything to a customer. Book value per share nearly doubling is not compounding, it is dilution dressed up as progress — real owners' capital per share is being consumed, not created. I don't need to know whether quantum computers work in 2040; I know that paying five billion for negative returns on capital and vanishing gross margin requires believing something stupid, and I'd rather miss it.